Palliative CareSUPPORT+NCT07475312
SUPPORT+ Digital Self-Management and Clinical Support for Advanced Cancer
A study testing SUPPORT+ Digital Symptom Monitoring and Clinical Support in people with Palliative Care and Advanced Cancer, run by The University of Hong Kong at 1 site in Hong Kong.
Trial summary
The goal of this clinical trial is to learn whether SUPPORT+, a digital symptom monitoring and self-management mobile application, can improve health-related quality of life and clinical outcomes in adults with advanced cancer receiving palliative care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Palliative Care, Advanced Cancer
- What is being tested?
- SUPPORT+ Digital Symptom Monitoring and Clinical Support
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 633 participants
- Where
- 1 siteHong Kong
- Study dates
- 16 Jan 2023to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older
- Diagnosis of advanced malignancy
- Decision not to pursue further systemic anticancer treatment
- Receiving follow-up care at a participating palliative care clinic
- Community-dwelling
- Ownership of a smartphone
Show all 10Show fewer
- Adequate cognitive capacity to provide informed consent
- Willingness to receive notifications from the SUPPORT+ mobile application
- Presence of at least one symptom related to advanced cancer
- Ability for the patient or a designated primary caregiver to use the mobile application
Who cannot join
- Receiving systemic anticancer therapy with radical or palliative intent
- Estimated life expectancy of less than 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status greater than 3
Trial locations and contacts
1 site in 1 country.
Hong Kong1 site
1. Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong SAR
Hong Kong
About this study
Official title: SUPPORT+ Digital Self-Management and Clinical Support for Patients With Advanced Cancer in the Community: A Randomized Controlled Trial
The goal of this clinical trial is to learn whether SUPPORT+, a digital symptom monitoring and self-management mobile application, can improve health-related quality of life and clinical outcomes in adults with advanced cancer receiving palliative care.
The main questions this study aims to answer are:
Read more
- Does use of SUPPORT+ help maintain or improve health-related quality of life compared with usual palliative care?
- Does SUPPORT+ reduce functional decline and acute health care use, such as hospitalisations, compared with usual care?
Researchers will compare patients using the SUPPORT+ mobile application with patients receiving usual palliative care to see if digital symptom monitoring combined with automated self-management guidance and nurse follow-up improves patient-reported and clinical outcomes.
Participants assigned to the SUPPORT+ arm will:
- Use the SUPPORT+ mobile application for weekly symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS)
- Receive automated self-management advice based on reported symptoms
- Receive follow-up contact from a nurse when severe or concerning symptoms are identified
- Continue to receive usual palliative care throughout the study period
Participants assigned to the usual care arm will:
- Receive usual palliative care provided by their clinical team
- Complete study assessments at scheduled time points
- Not receive digital symptom monitoring, automated self-management advice, or nurse follow-up through the SUPPORT+ application
Read the detailed description
Patients with advanced cancer often experience substantial physical and psychological symptom burden that negatively affects health-related quality of life and may lead to avoidable emergency department visits and hospitalisations. Digital symptom monitoring tools may support earlier identification of symptom deterioration and timely intervention, but evidence in palliative care populations remains limited.
This multicentre, randomised controlled trial evaluated whether adding SUPPORT+, a mobile application for symptom monitoring with automated self-management guidance and nurse follow-up, to usual palliative care could improve patient-reported outcomes and healthcare utilisation among adults with advanced cancer.
Community-dwelling adults aged 18 years or older with advanced malignancy who had decided not to pursue further systemic anticancer treatment and were receiving follow-up at palliative care clinics in six public hospitals in Hong Kong were recruited. Eligible participants were required to own a smartphone, have adequate cognitive capacity to provide informed consent, be willing to receive application notifications, and report at least one symptom related to advanced cancer. Patients with an estimated life expectancy of less than three months or an Eastern Cooperative Oncology Group (ECOG) performance status greater than 3 were excluded. Caregivers were permitted to act as proxy users when participants were unable to use the application independently.
Participants were randomly assigned in a 1:1 ratio to either the intervention group (SUPPORT+ plus usual care) or the usual care group. Randomisation was stratified by age, chronic opioid use, and app user (patient or caregiver proxy). Clinicians providing routine palliative care were not informed of group allocation.
All participants received standard palliative care according to usual clinical practice. Participants in the intervention group additionally received full access to the SUPPORT+ mobile application for 18 weeks. Weekly notifications prompted symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS). Following each submission, participants received automated symptom-specific self-management advice. Reports containing any severe symptom triggered real-time alerts to palliative care nurses, who contacted participants during office hours to provide clinical guidance, including medication advice, self-management strategies, expedited clinic review, or recommendations for urgent care when appropriate. Participants could also initiate nurse contact through the application during office hours.
Assessments were conducted at baseline, week 9, and week 18. The primary outcome was change in health-related quality of life measured using the EQ-5D-5L utility score. Secondary outcomes included self-rated health (EQ-VAS), self-efficacy for managing chronic disease, ECOG performance status, emergency department visits, hospitalisations, length of hospital stay, and completion of advance directives. Healthcare utilisation data were retrieved from electronic medical records.
- Conditions
- Palliative Care, Advanced Cancer
- Being tested
- SUPPORT+ Digital Symptom Monitoring and Clinical Support
- Keywords
- health related quality of life, hospitalisation, digital symptom monitoring, Palliative Care Outcome Scale (IPOS)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SUPPORT+ Digital Symptom Monitoring and Clinical SupportBehavioural
SUPPORT+ is a mobile application that prompts participants to complete weekly symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS). After each submission, the application provides automated, symptom-specific self-management advice. Reports indicating severe symptoms trigger real-time alerts to palliative care nurses, who contact participants during office hours to provide clinical guidance, including medication advice, self-management strategies, expedited clinic review, or recommendations for urgent medical care when appropriate. Participants may also initiate nurse contact through the application during office hours.
| Study group | Role | What they receive |
|---|---|---|
| SUPPORT+ Plus Usual Palliative Care | Experimental | Participants in this arm receive usual palliative care supplemented by SUPPORT+, a mobile application providing weekly digital symptom monitoring, automated self-management guidance, and nurse follow-up for severe symptoms, for a duration of 18 weeks. After each submission, participants received symptom-specific self-management advice. Any report containing a severe symptom was transmitted in real time to palliative care nurses, who contacted patients within one working day during office hours to provide clinical support, including medication adjustments, self-management strategies, expedited appointments, or advice to attend the emergency department or admit to hospital. Participants could also contact nurses during office hours via the "Nurse Consult" feature; outside these hours, they were advised to seek urgent medical care. Receives: Behavioral: SUPPORT+ Digital Symptom Monitoring and Clinical Support |
| Usual Palliative Care | No intervention | Participants in this arm receive usual palliative care provided by their clinical team according to standard practice, without access to digital symptom monitoring, automated self-management guidance, or nurse follow-up through the SUPPORT+ application. They could access only the publicly available educational materials within the SUPPORT+ application. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Health-Related Quality of Life (EQ-5D-5L index)
Change in health-related quality of life measured using the EQ-5D-5L index (utility) score. The EQ-5D-5L assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on five levels from 1 (no problems) to 5 (extreme problems). Utility scores are derived using the Hong Kong value set and range from -0.865 (worst health state) to 1 (perfect health).
Measured: Baseline to 18 weeks
Change in Self-rated health measured by EQ-VAS
Change in self-rated health measured using the EQ-5D visual analogue scale (EQ-VAS), on which participants rate their overall health on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health).
Measured: Baseline to 18 weeks
Secondary outcomes (4)
Change in Self-Efficacy for Managing Chronic Disease
Change in self-efficacy measured using the 6-item Self-Efficacy for Managing Chronic Disease Scale (SEMCD-6S). The SEMCD-6S assesses an individual's confidence in managing symptoms and the impact of a chronic condition on daily life, including fatigue, pain, emotional distress, symptom control, and self-management activities. Each item is rated on a numeric scale from 1 (not at all confident) to 10 (totally confident). The overall score is calculated as the mean of the six items, with higher scores indicating greater self-efficacy.
Measured: Baseline to 18 weeks
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status
Change in functional status measured using the Eastern Cooperative Oncology Group (ECOG) Performance Status scale. The ECOG scale is a clinician-rated measure of a patient's level of functioning and ability to perform daily activities, ranging from 0 to 4, with lower scores indicating better functional status. Scores are defined as follows: 0 = fully active with no restrictions; 1 = restricted in physically strenuous activity but ambulatory and able to perform light work; 2 = ambulatory and capable of all self-care but unable to work; 3 = capable of only limited self-care and confined to bed or chair more than 50% of waking hours; 4 = completely disabled and unable to perform any self-care.
Measured: Baseline to 18 weeks
Emergency Department Visits
Number of emergency department visits recorded in electronic medical records.
Measured: Baseline to 18 weeks
Hospitalisations
Number of hospital admissions and total length of hospital stay recorded in electronic medical records.
Measured: Baseline to 18 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start16 Jan 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Palliative CareStudies of the same condition, open and under way.
- More trials run by The University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study uses a parallel-group randomized controlled trial design. Eligible participants are randomly assigned in a 1:1 ratio to either the intervention arm (SUPPORT+ plus usual palliative care) or the control arm (usual palliative care alone). Participants remain in their assigned group for the duration of the 18-week study period. Outcomes are assessed at predefined time points and compared between groups to evaluate the effects of adding digital symptom monitoring with automated self-management guidance and nurse follow-up to usual palliative care.
- Masking
- None (open label)
- Enrolment
- 633 participants (actual)
Sponsor and investigators
- Lead sponsor
- The University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wing Lok Wendy Chan, The University of Hong Kong
- Investigators
- Wing-Lok Wendy Chan, MBBS, Principal investigator, The University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07475312
- Sponsor's protocol ID
- CIRB-2023-011-3
- Acronym
- SUPPORT+
- Status last verified
- Mar 2026
- First submitted
- 11 Mar 2026
- Last updated
- 2 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because data sharing was not approved by the Institutional Review Board and is restricted to protect participant privacy and confidentiality.
Publications
Chan WL, Soong IS, Lim MY, Tin WW, Siu SW, Ng J, Leung C, Leung A, Tai YL, Lam CM, Hou LY, Lo R, Lee VH, Yuen KK, Kwong D, Hui R. Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2026 Jun 1;9(6):e2615509. doi: 10.1001/jamanetworkopen.2026.15509.
PubMed 42224222
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SUPPORT+ Digital Self-Management and Clinical Support for Patients With Advanced Cancer in the Community: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07475312
- Acronym / sponsor ID
- SUPPORT+ / CIRB-2023-011-3
- Conditions
- Palliative Care, Advanced Cancer
- Keywords
- health related quality of life, hospitalisation, digital symptom monitoring, Palliative Care Outcome Scale (IPOS)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 633 participants (actual)
- Lead sponsor
- The University of Hong KongUniversity, hospital or other
- Study start
- 16 Jan 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 16 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether SUPPORT+, a digital symptom monitoring and self-management mobile application, can improve health-related quality of life and clinical outcomes in adults with advanced cancer receiving palliative care.
The main questions this study aims to answer are:
- Does use of SUPPORT+ help maintain or improve health-related quality of life compared with usual palliative care?
- Does SUPPORT+ reduce functional decline and acute health care use, such as hospitalisations, compared with usual care?
Researchers will compare patients using the SUPPORT+ mobile application with patients receiving usual palliative care to see if digital symptom monitoring combined with automated self-management guidance and nurse follow-up improves patient-reported and clinical outcomes.
Participants assigned to the SUPPORT+ arm will:
- Use the SUPPORT+ mobile application for weekly symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS)
- Receive automated self-management advice based on reported symptoms
- Receive follow-up contact from a nurse when severe or concerning symptoms are identified
- Continue to receive usual palliative care throughout the study period
Participants assigned to the usual care arm will:
- Receive usual palliative care provided by their clinical team
- Complete study assessments at scheduled time points
- Not receive digital symptom monitoring, automated self-management advice, or nurse follow-up through the SUPPORT+ application
Detailed description
Patients with advanced cancer often experience substantial physical and psychological symptom burden that negatively affects health-related quality of life and may lead to avoidable emergency department visits and hospitalisations. Digital symptom monitoring tools may support earlier identification of symptom deterioration and timely intervention, but evidence in palliative care populations remains limited.
This multicentre, randomised controlled trial evaluated whether adding SUPPORT+, a mobile application for symptom monitoring with automated self-management guidance and nurse follow-up, to usual palliative care could improve patient-reported outcomes and healthcare utilisation among adults with advanced cancer.
Community-dwelling adults aged 18 years or older with advanced malignancy who had decided not to pursue further systemic anticancer treatment and were receiving follow-up at palliative care clinics in six public hospitals in Hong Kong were recruited. Eligible participants were required to own a smartphone, have adequate cognitive capacity to provide informed consent, be willing to receive application notifications, and report at least one symptom related to advanced cancer. Patients with an estimated life expectancy of less than three months or an Eastern Cooperative Oncology Group (ECOG) performance status greater than 3 were excluded. Caregivers were permitted to act as proxy users when participants were unable to use the application independently.
Participants were randomly assigned in a 1:1 ratio to either the intervention group (SUPPORT+ plus usual care) or the usual care group. Randomisation was stratified by age, chronic opioid use, and app user (patient or caregiver proxy). Clinicians providing routine palliative care were not informed of group allocation.
All participants received standard palliative care according to usual clinical practice. Participants in the intervention group additionally received full access to the SUPPORT+ mobile application for 18 weeks. Weekly notifications prompted symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS). Following each submission, participants received automated symptom-specific self-management advice. Reports containing any severe symptom triggered real-time alerts to palliative care nurses, who contacted participants during office hours to provide clinical guidance, including medication advice, self-management strategies, expedited clinic review, or recommendations for urgent care when appropriate. Participants could also initiate nurse contact through the application during office hours.
Assessments were conducted at baseline, week 9, and week 18. The primary outcome was change in health-related quality of life measured using the EQ-5D-5L utility score. Secondary outcomes included self-rated health (EQ-VAS), self-efficacy for managing chronic disease, ECOG performance status, emergency department visits, hospitalisations, length of hospital stay, and completion of advance directives. Healthcare utilisation data were retrieved from electronic medical records.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study uses a parallel-group randomized controlled trial design. Eligible participants are randomly assigned in a 1:1 ratio to either the intervention arm (SUPPORT+ plus usual palliative care) or the control arm (usual palliative care alone). Participants remain in their assigned group for the duration of the 18-week study period. Outcomes are assessed at predefined time points and compared between groups to evaluate the effects of adding digital symptom monitoring with automated self-management guidance and nurse follow-up to usual palliative care.
| Arm | Type | Receives |
|---|---|---|
| SUPPORT+ Plus Usual Palliative Care | Experimental | Behavioral: SUPPORT+ Digital Symptom Monitoring and Clinical SupportParticipants in this arm receive usual palliative care supplemented by SUPPORT+, a mobile application providing weekly digital symptom monitoring, automated self-management guidance, and nurse follow-up for severe symptoms, for a duration of 18 weeks. After each submission, participants received symptom-specific self-management advice. Any report containing a severe symptom was transmitted in real time to palliative care nurses, who contacted patients within one working day during office hours to provide clinical support, including medication adjustments, self-management strategies, expedited appointments, or advice to attend the emergency department or admit to hospital. Participants could also contact nurses during office hours via the "Nurse Consult" feature; outside these hours, they were advised to seek urgent medical care. |
| Usual Palliative Care | No intervention | –Participants in this arm receive usual palliative care provided by their clinical team according to standard practice, without access to digital symptom monitoring, automated self-management guidance, or nurse follow-up through the SUPPORT+ application. They could access only the publicly available educational materials within the SUPPORT+ application. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Adults aged 18 years or older
- Diagnosis of advanced malignancy
- Decision not to pursue further systemic anticancer treatment
- Receiving follow-up care at a participating palliative care clinic
- Community-dwelling
Key exclusion criteria (3 listed)
- Receiving systemic anticancer therapy with radical or palliative intent
- Estimated life expectancy of less than 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status greater than 3
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SUPPORT+ Digital Symptom Monitoring and Clinical SupportSUPPORT+ is a mobile application that prompts participants to complete weekly symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS). After each submission, the application provides automated, symptom-specific self-management advice. Reports indicating severe symptoms trigger real-time alerts to palliative care nurses, who contact participants during office hours to provide clinical guidance, including medication advice, self-management strategies, expedited clinic review, or recommendations for urgent medical care when appropriate. Participants may also initiate nurse contact through the application during office hours. | Behavioural | SUPPORT+ Plus Usual Palliative Care |
Primary outcome
Change in Health-Related Quality of Life (EQ-5D-5L index)
Time frame: Baseline to 18 weeks
Change in health-related quality of life measured using the EQ-5D-5L index (utility) score. The EQ-5D-5L assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on five levels from 1 (no problems) to 5 (extreme problems). Utility scores are derived using the Hong Kong value set and range from -0.865 (worst health state) to 1 (perfect health).
Change in Self-rated health measured by EQ-VAS
Time frame: Baseline to 18 weeks
Change in self-rated health measured using the EQ-5D visual analogue scale (EQ-VAS), on which participants rate their overall health on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health).
4 secondary outcomes
Change in Self-Efficacy for Managing Chronic Disease
Time frame: Baseline to 18 weeks
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status
Time frame: Baseline to 18 weeks
Emergency Department Visits
Time frame: Baseline to 18 weeks
Hospitalisations
Time frame: Baseline to 18 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
- Derived from this study: PubMed 42224222Chan WL, Soong IS, Lim MY, Tin WW, Siu SW, Ng J, Leung C, Leung A, Tai YL, Lam CM, Hou LY, Lo R, Lee VH, Yuen KK, Kwong D, Hui R. Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2026 Jun 1;9(6):e2615509. doi: 10.1001/jamanetworkopen.2026.15509.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because data sharing was not approved by the Institutional Review Board and is restricted to protect participant privacy and confidentiality.
Related trials for Palliative Care
Not yet recruitingObservational study
IN-TALK: Co-producing a Hospice Intimacy Support Toolkit in England
Communication About Intimacy Needs in Hospice and Palliative Care
Not yet recruitingPhase 2
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1/2
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Malignant Solid Neoplasm
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
Not yet recruiting
Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wing-Lok Wendy Chan, MBBS principal investigator
The University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SUPPORT+ Digital Symptom Monitoring and Clinical Support in people with Palliative Care and Advanced Cancer, run by The University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Health-Related Quality of Life (EQ-5D-5L index) (time frame: Baseline to 18 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07475312, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.